Skip to main content
SpringerLink
Log in

Wirkstoff überwindet Therapieresistenz

  • KOMPAKT
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Mian et al.: PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome- positive (Ph+) leukemias harboring the T315I mutation, in Leukemia, 14. November 2014, doi: 10.1038/leu.2014.326.

Download references

Author information

Consortia

Springer Medizin-Verlag

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Springer Medizin-Verlag. Wirkstoff überwindet Therapieresistenz. best practice onkologie 10, 4 (2015). https://doi.org/10.1007/s11654-015-0165-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-015-0165-x

Search

Navigation